Literature DB >> 17341802

Polonium-210 as a poison.

John Harrison1, Rich Leggett, David Lloyd, Alan Phipps, Bobby Scott.   

Abstract

The death of Alexander Litvinenko on 23 November 2006 has brought into focus scientific judgements concerning the radiotoxicity of polonium-210 ((210)Po). This paper does not consider the specific radiological circumstances surrounding the tragic death of Mr Litvinenko; rather, it provides an evaluation of published human and animal data and models developed for the estimation of alpha radiation doses from (210)Po and the induction of potentially fatal damage to different organs and tissues. Although uncertainties have not been addressed comprehensively, the reliability of key assumptions is considered. Concentrating on the possibility of intake by ingestion, the use of biokinetic and dosimetric models to estimate organ and tissue doses from (210)Po is examined and model predictions of the time-course of dose delivery are illustrated. Estimates are made of doses required to cause fatal damage, taking account of the possible effects of dose protraction and the relative biological effectiveness (RBE) of alpha particles compared to gamma and x-rays. Comparison of LD(50) values (dose to cause death for 50% of people) for different tissues with the possible accumulation of dose to these tissues suggests that bone marrow failure is likely to be an important component of multiple contributory causes of death occurring within a few weeks of an intake by ingestion. Animal data on the effects of (210)Po provide good confirmatory evidence of intakes and doses required to cause death within about 3 weeks. The conclusion is reached that 0.1-0.3 GBq or more absorbed to blood of an adult male is likely to be fatal within 1 month. This corresponds to ingestion of 1-3 GBq or more, assuming 10% absorption to blood. Well-characterised reductions in white cell counts would be observed. Bone marrow failure is likely to be compounded by damage caused by higher doses to other organs, including kidneys and liver. Even if the bone marrow could be rescued, damage to other organs can be expected to prove fatal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341802     DOI: 10.1088/0952-4746/27/1/001

Source DB:  PubMed          Journal:  J Radiol Prot        ISSN: 0952-4746            Impact factor:   1.394


  15 in total

Review 1.  Post-mortem clinical pharmacology.

Authors:  R E Ferner
Journal:  Br J Clin Pharmacol       Date:  2008-05-29       Impact factor: 4.335

2.  Calculating hematopoietic-mode-lethality risk avoidance associated with radionuclide decorporation countermeasures related to a radiological terrorism incident.

Authors:  Bobby R Scott
Journal:  Dose Response       Date:  2009-10-08       Impact factor: 2.658

3.  A study on the effect of the internal exposure to (210)Po on the excretion of urinary proteins in rats.

Authors:  Baki Sadi; Chunsheng Li; Raymond Ko; Joseph Daka; Hamdi Yusuf; Heather Wyatt; Joel Surette; Nick Priest; Nobuyuki Hamada
Journal:  Radiat Environ Biophys       Date:  2016-03-09       Impact factor: 1.925

Review 4.  Astatine-211: production and availability.

Authors:  Michael R Zalutsky; Marek Pruszynski
Journal:  Curr Radiopharm       Date:  2011-07

5.  Natural variation in 210Po and 210Pb activity concentrations in the urine of Finnish population groups.

Authors:  Maarit Muikku; Tarja Heikkinen; Dina Solatie; Pia Vesterbacka
Journal:  Radiat Environ Biophys       Date:  2011-09-16       Impact factor: 1.925

6.  Ion, X-ray, UV and Neutron Microbeam Systems for Cell Irradiation.

Authors:  A W Bigelow; G Randers-Pehrson; G Garty; C R Geard; Y Xu; A D Harken; G W Johnson; D J Brenner
Journal:  AIP Conf Proc       Date:  2010-08-08

Review 7.  Radiologic and nuclear events: contingency planning for hematologists/oncologists.

Authors:  David M Weinstock; Cullen Case; Judith L Bader; Nelson J Chao; C Norman Coleman; Richard J Hatchett; Daniel J Weisdorf; Dennis L Confer
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

Review 8.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

9.  Internal dose assessment of 210Po using biokinetic modeling and urinary excretion measurement.

Authors:  Wei Bo Li; Udo Gerstmann; Augusto Giussani; Uwe Oeh; Herwig G Paretzke
Journal:  Radiat Environ Biophys       Date:  2007-09-25       Impact factor: 1.925

10.  210Po Log-normal distribution in human urines: survey from central Italy people.

Authors:  D Sisti; M B L Rocchi; M A Meli; D Desideri
Journal:  Toxicol Mech Methods       Date:  2009-03       Impact factor: 2.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.